Prohibitin-targeting peptide 1 (also known as prohibitin-TP01 and TP01; trade name Adipotide FTPP ) is a peptidomimetic with sequence CKGGRAKDC-GG-D(KLAKLAK)2. It is an experimental proapoptotic drug that has been shown to cause rapid weight loss in mice and rhesus monkeys. Its mechanism of action is to target specific blood vessels supplying adipose tissue with blood. Cause the vessels to shrink and the fat cells fed by those vessels to undergo apoptosis. TP01 is designed to bind to two receptors. ANXA2 and prohibitin, that are specific to blood vessels supplying white adipose tissue.
Description AdipotideTM, or Prohibitin-Targeting Peptide 1 (Prohibitin-TP01). It is an anti-obesity peptide that specifically targets and kills blood vessels supplying white fat tissue. It is the peptidomimetic CKGGRAKDC-GG-D(KLAKLAK)2. Adipotide targeted the vasculature of white adipose tissue and resulted in ~30% weight reduction in obese mice over a period of 4 weeks. Therefore, unlike nonspecific angiogenesis inhibitors, adipokine is systemically targeted to the endothelium of fat through a ligand-directed mechanism and disrupts the vascular supply of white adipose tissue, at least in rodent obesity models. Moreover, an annexin A2–prohibitin receptor system targeted by adipotide peptide has been reported recently in the white adipose tissue vasculature of human patients.
More Introduction:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666164/
